Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May;15(5):523-36.
doi: 10.1016/j.bbmt.2008.12.489. Epub 2009 Feb 12.

Busulfan in hematopoietic stem cell transplantation

Stefan O Ciurea  1 , Borje S Andersson
Affiliations
Review

Busulfan in hematopoietic stem cell transplantation

Stefan O Ciurea et al. Biol Blood Marrow Transplant. 2009 May.

Abstract

The development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic stem cell transplantation has changed transplantation for myelogenous malignancies. Bypassing the oral route to achieve 100% bioavailability translated into improved control over drug administration, with increased safety and reliability of generating therapeutic Bu levels, maximizing antileukemic efficacy. Bu-nucleoside analog-based conditioning chemotherapy, thus far represented by fludarabine (Flu), is becoming the conditioning chemotherapy regimen of choice for patients with acute myelogenous leukemia (AML) at many transplant centers. The use of busulfan Bu-based conditioning is extending rapidly also to hematopoietic stem cell transplantation (HSCT) for lymphoid malignancies, genetic diseases, and umbilical cord blood transplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Potential peri-transplant interventions added to the IV BuFlu conditioning regimen for hematopoietic stem cell transplantation.
See this image and copyright information in PMC

References

    1. Haddow A, Timmis GM. Myeleran in chronic myeloid leukemia. Chemical constitution and biological action. Lancet. 1953;31:207–208. - PubMed
    1. Galton GA. Myeleran in chronic myeloid leukemia. Results of treatment. Lancet. 1953;31:208–213. - PubMed
    1. Santos GW, Tutschka PJ. Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia. J Natl Cancer Inst. 1974;53:1781–1785. - PubMed
    1. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347–1353. - PubMed
    1. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for acute leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70:1382–1388. - PubMed

Publication types

MeSH terms